13 completed, 4 unknown, 2 terminated, 1 active not recruiting. 23 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 23 | Completed 13, Unknown 4, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1, Withdrawn 1 |
Follow Farxiga: new trials by email Literature Review of Farxiga trials Research Report on Farxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) Placebo, Dapagliflozin 10mg Tab - Gestational Hypertension, Hypertension in Pregnancy | Phase 4 | Recruiting | University of Michigan | 200 | 2025-03-02 | 2026-03-04 |
| Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes dapagliflozin, ACE inhibitor - Diabetic Kidney Disease, Type 1 Diabetes | Phase 4 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 54 | 2024-07-01 | 2024-08-01 |
| proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 Dapagliflozin 10 MG Oral Tablet [Farxiga], Placebo - Acute Kidney Injury, Cardiac Surgery | Phase 4 | Active not recruiting | Amsterdam UMC | 784 | 2023-06-09 | 2025-05-18 |
| Dapagliflozin at Discharge on Hospital Heart Failure Readmission Dapagliflozin, Placebo - Heart Failure, Diabetes | Phase 4 | Completed | Emory University | 105 | 2020-07-29 | 2024-06-14 |
| Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects Dapagliflozin, Placebo - Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 32 | 2019-05-23 | 2024-03-04 |
| Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial Diabetes Medicines, Dapagliflozin - Type 2 Diabetes Mellitus | Phase 4 | Completed | Mackay Memorial Hospital | 76 | 2019-04-01 | 2023-03-22 |
| Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Phase 4 | Terminated | Sabyasachi Sen | 15 | 2018-10-22 | 2023-06-05 |
| Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Placebo, Exenatide, Dapagliflozin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 107 | 2018-02-28 | 2023-07-24 |
| Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease Dapagliflozin 10 MG [Farxiga], Placebo Oral Tablet - Coronary Disease With Diabetes Mellitus | Phase 4 | Unknown | Sheba Medical Center | 61 | 2018-02-01 | 2018-01-17 |
| Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Dapagliflozin, Exenatide, Placebo - Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 90 | 2017-12-15 | 2023-07-20 |
| Dapagliflozin in PRESERVED Ejection Fraction Heart Failure Dapagliflozin 10Mg Oral Tablet, Dapagliflozin matching placebo - Chronic Heart Failure With Preserved Systolic Function | Phase 4 | Completed | Saint Luke's Health System | 324 | 2017-03-01 | 2022-10-19 |
| Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery Dapagliflozin 10 mg, Glibenclamide 5 mg - Diabetes Mellitus, Type 2, Coronary Artery Disease | Phase 4 | Completed | University of Campinas, Brazil | 98 | 2017-01-01 | 2023-03-10 |
| Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration Dapagliflozin, Metformin, Glipizide 5 MG - Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 72 | 2016-12-20 | 2023-11-30 |
| Effect of Anti-diabetic Drugs on Glycemic Variability Dapagliflozin, Gliclazide MR - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Centro de Diabetes Curitiba Ltda | 135 | 2016-10-01 | 2020-03-04 |
| Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration - Diabetes Mellitus, Type 2 | Phase 4 | Withdrawn | Weill Medical College of Cornell University | 2016-06-01 | 2017-03-03 | |
| Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Metformin, Dapagliflozin, Metformin up-titration - Diabetes Mellitus, Hypoglycemic Episodes | Phase 4 | Unknown | Research Clinical Centre of the Russian Railways, JSC | 100 | 2016-04-01 | 2016-03-25 |
| Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Dapagliflozin, Dapagliflozin matching placebo - Chronic Heart Failure With Reduced Systolic Function | Phase 4 | Completed | Saint Luke's Health System | 263 | 2016-03-03 | 2022-04-21 |
| Effect of Dapagliflozin on Inflammation and Endothelial Function Dapagliflozin, Placebo - Type 2 Diabetes Mellitus | Phase 4 | Terminated | Baylor College of Medicine | 17 | 2015-11-01 | 2020-04-08 |
| An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin dapagliflozin, Placebo - Type 2 Diabetes | Phase 4 | Completed | University at Buffalo | 52 | 2015-11-01 | 2019-10-30 |
Showing 20 of 23. Sign in to see all of them.
Diabetes Mellitus, Type 2 (15) · Diabetes Mellitus (4) · Heart Failure (3) · Acute Kidney Injury (1) · Albuminuria (1) · Cardiovascular Diseases (1) · Carotid Artery Diseases (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Nephropathies (1) · Hyperkalemia (1) · Hypertension, Pregnancy-Induced (1) · Obesity (1) · Pre-Eclampsia (1)
The University of Texas Health Science Center at San Antonio (4) · Saint Luke's Health System (2) · Amsterdam UMC (1) · AstraZeneca (1) · Baylor College of Medicine (1) · Baylor Research Institute (1) · Centro de Diabetes Curitiba Ltda (1) · Emory University (1) · Gulf Regional Research & Educational Services, LLC (1) · Mackay Memorial Hospital (1) · Research Clinical Centre of the Russian Railways, JSC (1) · Sabyasachi Sen (1) · Sheba Medical Center (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University at Buffalo (1)
United States (16) · Brazil (2) · China (1) · Israel (1) · Netherlands (1) · Russia (1) · Taiwan (1)
Eugenio Cersosimo, MD,PhD (2) · Mikhail Kosiborod, MD (2) · Alexander Ametov, prof., MD (1) · Alpana P Shukla, MD (1) · Andre GD Vianna, MD (1) · Ashley Hesson, MD, PhD (1) · Gianluca Iacobellis, MD, PhD (1) · Guillermo Umpierrez, MD (1) · Mandeep Bajaj, MD (1) · Mei Zhang (1) · Paresh Dandona, MD, PhD (1) · Ralph DeFronzo, MD (1) · Robert Klempfner, Proffesor (1) · Sabyasachi Sen, MD, PhD (1)
PMID 31081589, PMID 37203441, PMID 39421941, PMID 30222367, PMID 31384310, PMID 32044999, PMID 34711976, PMID 35235659, PMID 35603596, PMID 37869881, PMID 38639353, PMID 38639697, PMID 39865301, PMID 40153894, PMID 40379310, PMID 41888924, PMID 42530910
R01DK107680 (1)